1h Free Analyst Time
The non-invasive glucose monitoring devices market is forecasted to grow by USD 43.7 million during 2024-2029, accelerating at a CAGR of 20.4% during the forecast period. The report on the non-invasive glucose monitoring devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of diabetes and initiatives by governments, frequent launch of non-invasive glucose monitoring devices, and increasing demand for non-invasive procedures.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The non-invasive glucose monitoring devices market is segmented as below:
By Product
- Wearable
- Non-wearable
By End-user
- Home care settings
- Hospitals
- Clinics
By Component
- Measuring device
- Transmitter
- Software or app
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the non-invasive glucose monitoring devices market covers the following areas:
- Non-Invasive Glucose Monitoring Devices Market sizing
- Non-Invasive Glucose Monitoring Devices Market forecast
- Non-Invasive Glucose Monitoring Devices Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Product
9 Market Segmentation by End-user
10 Market Segmentation by Component
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global non-invasive glucose monitoring devices market: Abbott Laboratories, Ascensia Diabetes Care Holdings AG, BlueSemi, BoydSense SAS, Cnoga, Dexcom Inc., DiaMonTech AG, ESER Co., F. Hoffmann La Roche Ltd., Gluco Rx Ltd., HAGAR, LifeScan IP Holdings LLC, Medtronic Plc, Nemaura Medical Inc., NOVIOSENSE BV, Persperion Diagnostics, Senseonics Holdings Inc., and Taiwan Biophotonic Co..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing focus on collaborations for business expansion."
According to the report, one of the major drivers for this market is the increasing prevalence of diabetes and initiatives by governments.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Ascensia Diabetes Care Holdings AG
- BlueSemi
- BoydSense SAS
- Cnoga
- Dexcom Inc.
- DiaMonTech AG
- ESER Co.
- F. Hoffmann La Roche Ltd.
- Gluco Rx Ltd.
- HAGAR
- LifeScan IP Holdings LLC
- Medtronic Plc
- Nemaura Medical Inc.
- NOVIOSENSE BV
- Persperion Diagnostics
- Senseonics Holdings Inc.
- Taiwan Biophotonic Co.
